Tetraethylene glycol diacrylate (TEGDMA) is a liquid monomer commonly used in dental restorative materials. It is synthesized through the reaction of tetraethylene glycol with acrylic acid. TEGDMA, when polymerized, creates a rigid, durable material that is used to bind dental fillings to teeth. However, it has been linked to potential health concerns, including allergic reactions, cytotoxicity, and potential for developmental toxicity. Research on TEGDMA focuses on improving its biocompatibility, exploring alternative monomers, and developing new formulations that minimize its potential risks while maintaining its desirable properties. TEGDMA is studied to better understand its interactions with biological systems and to develop safer and more effective dental materials. '
| ID Source | ID |
|---|---|
| PubMed CID | 28803 |
| CHEMBL ID | 1492729 |
| SCHEMBL ID | 25514 |
| MeSH ID | M0101887 |
| Synonym |
|---|
| 2-propenoic acid, oxybis(2,1-ethanediyloxy-2,1-ethanediyl) ester |
| tetraethylene glycol diacrylate |
| 17831-71-9 |
| NCGC00091030-01 |
| NCGC00091030-02 |
| oxybis(2,1-ethanediyloxy-2,1-ethanediyl)diacrylate |
| acrylic acid, oxybis(ethyleneoxyethylene) ester |
| sr 268 |
| ccris 3434 |
| 2-propenoic acid, oxybis(2,1-ethanediyloxy-2,1-ethanediyl)ester |
| einecs 241-789-3 |
| tetraethyleneglycol diacrylate |
| viscoat 335hp |
| acrylic acid, diester with tetraethylene glycol |
| aronix m 240 |
| MLS002222349 , |
| smr001307285 |
| tetra(ethylene glycol) diacrylate, technical grade, contains 150-200 ppm mehq as inhibitor, 100-150 ppm hq as inhibitor |
| 13-oxo-3,6,9,12-tetraoxapentadec-14-en-1-yl acrylate |
| T1569 |
| 2-[2-[2-(2-prop-2-enoyloxyethoxy)ethoxy]ethoxy]ethyl prop-2-enoate |
| NCGC00091030-05 |
| NCGC00091030-03 |
| NCGC00091030-06 |
| NCGC00091030-04 |
| 2-propenoic acid, 1,1'-(oxybis(2,1-ethanediyloxy-2,1-ethanediyl)) ester |
| cas-17831-71-9 |
| tox21_202993 |
| tox21_202541 |
| dtxcid606107 |
| NCGC00260090-01 |
| NCGC00260538-01 |
| dtxsid2026107 , |
| e40oe44a24 , |
| peg-4 diacrylate |
| unii-e40oe44a24 |
| ttegda |
| tetra(ethylene glycol) diacrylate |
| acrylic acid 2-[2-[2-(2-acryloyloxyethoxy)ethoxy]ethoxy]ethyl ester |
| bdbm97021 |
| 2-propenoic acid 2-[2-[2-[2-(1-oxoprop-2-enoxy)ethoxy]ethoxy]ethoxy]ethyl ester |
| cid_28803 |
| CHEMBL1492729 |
| SCHEMBL25514 |
| 2-propenoic acid, 1,1'-[oxybis(2,1-ethanediyloxy-2,1-ethanediyl)] ester |
| HCLJOFJIQIJXHS-UHFFFAOYSA-N |
| 13-oxo-3,6,9,12-tetraoxapentadec-14-en-1-yl acrylate # |
| peg 200 diacrylate |
| mfcd00008630 |
| tetraethylene glycol diacrylate, (stabilized with mehq) |
| tetraethylene glycol diacrylate (stabilized with mehq) |
| J-011367 |
| tetraethylene glycol diacrylate(20 cp(25 degrees c)) |
| FT-0704215 |
| 2,2'-(2,2'-oxybis(ethane-2,1-diyl)bis(oxy))bis(ethane-2,1-diyl) diacrylate |
| tetraethylene glycol diacrylate(tetegda) |
| ((oxybis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl) diacrylate |
| STARBLD0009642 |
| AS-80580 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| interleukin 8 | Homo sapiens (human) | Potency | 66.8242 | 0.0473 | 49.4806 | 74.9780 | AID651758 |
| Nrf2 | Homo sapiens (human) | Potency | 3.1623 | 0.0920 | 8.2222 | 23.1093 | AID624171 |
| pregnane X receptor | Rattus norvegicus (Norway rat) | Potency | 66.9452 | 0.0251 | 27.9203 | 501.1870 | AID651751 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 48.9963 | 3.1890 | 29.8841 | 59.4836 | AID1224846; AID1224894 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 10.8600 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 23.7149 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
| TDP1 protein | Homo sapiens (human) | Potency | 5.8048 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 5.3006 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 23.8959 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID588516; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063 |
| Smad3 | Homo sapiens (human) | Potency | 35.4813 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 58.3835 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 35.7168 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 50.1187 | 0.0013 | 7.7625 | 44.6684 | AID2120 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 20.0634 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 36.8375 | 0.0006 | 57.9133 | 22,387.1992 | AID1259378 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 66.1017 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
| progesterone receptor | Homo sapiens (human) | Potency | 23.5694 | 0.0004 | 17.9460 | 75.1148 | AID1346784; AID1346795 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 44.9770 | 0.0002 | 14.3764 | 60.0339 | AID588532; AID588533; AID720691; AID720692 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 36.9637 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 23.4762 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 7.8702 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 48.8072 | 0.3758 | 27.4851 | 61.6524 | AID588526; AID743217; AID743220 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 41.4422 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID588513; AID588514; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091 |
| 67.9K protein | Vaccinia virus | Potency | 19.1180 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
| P53 | Homo sapiens (human) | Potency | 70.7946 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 51.3858 | 0.0010 | 24.5048 | 61.6448 | AID588534; AID588535; AID743212; AID743215; AID743227 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 33.7746 | 0.0010 | 19.4141 | 70.9645 | AID588536; AID588537; AID743094; AID743140; AID743191 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 50.9509 | 0.0237 | 23.2282 | 63.5986 | AID588541; AID743222; AID743223; AID743241 |
| caspase-3 | Homo sapiens (human) | Potency | 58.3835 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
| IDH1 | Homo sapiens (human) | Potency | 20.5962 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 16.2524 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 68.9385 | 0.0016 | 28.0151 | 77.1139 | AID1224895 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 24.9558 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 12.1582 | 0.0578 | 21.1097 | 61.2679 | AID1159526 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 45.5980 | 0.0391 | 47.5451 | 146.8240 | AID1224845; AID1224896 |
| Caspase-7 | Cricetulus griseus (Chinese hamster) | Potency | 10.9117 | 0.0067 | 23.4960 | 68.5896 | AID1346980 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 31.6228 | 0.3162 | 12.4435 | 31.6228 | AID902 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 57.7315 | 0.0100 | 39.5371 | 1,122.0200 | AID588547 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 20.5962 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| caspase-3 | Cricetulus griseus (Chinese hamster) | Potency | 10.9117 | 0.0067 | 23.4960 | 68.5896 | AID1346980 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 19.4203 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 50.7982 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
| nuclear factor NF-kappa-B p105 subunit isoform 1 | Homo sapiens (human) | Potency | 17.9008 | 4.4668 | 24.8329 | 44.6684 | AID651749 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 37.6722 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID720636; AID743202; AID743219 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 1.2589 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 1.2589 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 1.2589 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 23.6887 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| geminin | Homo sapiens (human) | Potency | 3.1927 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 61.3611 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 23.2429 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 61.3611 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 16.5075 | 0.0266 | 22.4482 | 66.8242 | AID651802 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 35.4813 | 1.9953 | 25.5327 | 50.1187 | AID624288 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 28.0136 | 0.0119 | 17.9420 | 71.5630 | AID651632; AID720516 |
| Ataxin-2 | Homo sapiens (human) | Potency | 29.2611 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2, isoform CRA_a | Homo sapiens (human) | EC50 (µMol) | 91.1800 | 3.3810 | 3.3810 | 3.3810 | AID686991 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| LMP1 [Human herpesvirus 4] | human gammaherpesvirus 4 (Epstein-Barr virus) | AC50 | 24.9450 | 0.0680 | 39.9389 | 277.4300 | AID504861; AID504882; AID588398 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (32.61) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (9.09%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (90.91%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||